Theodore S. Johnson
0000-0002-4290-891X
Publication & Citation Trends
Publications
0 total
HGG-28. INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS OA
Cited by 0
Semantic Scholar
Abstract LB200: Indoximod or ibrutinib/indoximod based clinical chemo-immunotherapy drives conversion of extra-tumoral circulating stem-like precursor CD8+ T cells into clonally expanded, rejuvenated effector cells
Cited by 0
Semantic Scholar
Abstract LB344: Complement-mediated signaling during cross-presentation of tumor antigen augments T cell responses
Cited by 0
Semantic Scholar
CTIM-32. FIRST-IN-CHILDREN PHASE 1 TRIAL OF INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS: ANALYSIS OF SAFETY, TOLERABILITY, AND 5-YEAR OUTCOME OA
Cited by 0
Semantic Scholar
Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. OA
Cited by 71
Semantic Scholar
Abstract 2765: The indoleamine 2,3 dioxygenase-1 pathway drives intratumoral B cell maintenance
Cited by 0
Semantic Scholar
The indoleamine 2,3 dioxygenase pathway drives intratumoral B cell maintenance OA
Cited by 0
Semantic Scholar
Research Topics
Glioma Diagnosis and Treatment
(16)
Tryptophan and brain disorders
(16)
Cancer Immunotherapy and Biomarkers
(10)
Immune Cell Function and Interaction
(10)
CAR-T cell therapy research
(7)
Affiliations
Cincinnati Children's Hospital Medical Center
Emory University
Augusta University
Walter Reed National Military Medical Center
Coffs Harbour City Council